We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

59 hedge funds and large institutions have $62.7M invested in Viridian Therapeutics in 2018 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

243% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 7

129% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 7

16% more funds holding

Funds holding: 51 → 59 (+8)

4% more capital invested

Capital invested by funds: $60M → $62.7M (+$2.66M)

0.26% more ownership

Funds ownership: 1.72% → 1.98% (+0.26%)

Holders
59
Holders Change
+8
Holders Change %
+15.69%
% of All Funds
1.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
24
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.75M
2
6CM
683 Capital Management
New York
+$3.62M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$2.96M
4
AG
Artal Group
Luxembourg
+$2.9M
5
BlackRock
BlackRock
New York
+$1.7M

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$541K
2
Renaissance Technologies
Renaissance Technologies
New York
-$371K
3
OAM
Oxford Asset Management
United Kingdom
-$321K
4
VCA
Verdence Capital Advisors
Maryland
-$294K
5
BWP
BSW Wealth Partners
Colorado
-$232K
Name Holding Trade Value Shares
Change 		Change in
Stake
HighTower Advisors
26
HighTower Advisors
Illinois
$137K -$3.58K -33 -2%
Wells Fargo
27
Wells Fargo
California
$131K +$6.52K +60 +5%
Squarepoint
28
Squarepoint
New York
$129K +$38.7K +356 +41%
ACP
29
Aveo Capital Partners
Colorado
$117K -$72.5K -667 -37%
Citadel Advisors
30
Citadel Advisors
Florida
$117K +$121K +1,112 New
TI
31
Trexquant Investment
Connecticut
$110K -$1.41K -13 -1%
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$95K – – –
PWLP
33
Prio Wealth Limited Partnership
Massachusetts
$90K – – –
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$90K +$19.6K +180 +27%
TRCT
35
Tower Research Capital (TRC)
New York
$89K +$91.8K +845 New
MWNA
36
Marshall Wace North America
New York
$85K +$87.7K +807 New
AIG
37
American International Group
New York
$76K +$14.7K +135 +23%
Jane Street
38
Jane Street
New York
$71K +$73K +672 New
RCM
39
Radnor Capital Management
Pennsylvania
$70K – – –
State of Wisconsin Investment Board
40
State of Wisconsin Investment Board
Wisconsin
$70K – – –
PAM
41
Panagora Asset Management
Massachusetts
$63K – – –
Manulife (Manufacturers Life Insurance)
42
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$44K +$21.1K +194 +87%
Barclays
43
Barclays
United Kingdom
$41K +$23.5K +216 +127%
PCM
44
Prelude Capital Management
New York
$35K +$7.17K +66 +25%
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$33.1K +$13K +120 +62%
Macquarie Group
46
Macquarie Group
Australia
$30K +$31.2K +287 New
CBT
47
Capital Bank & Trust
California
$27K – – –
SO
48
STRS Ohio
Ohio
$25K – – –
Legal & General Group
49
Legal & General Group
United Kingdom
$22K +$9.45K +87 +71%
UBS Group
50
UBS Group
Switzerland
$18K +$1.09K +10 +6%
1
2
3

VRDN Hedge Fund Activity: Q1 2018 in Review

59 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2018, worth a combined $62.7M — up 4.4% from $60M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new VRDN positions and 7 closed out — a net gain of 9 holders — while 24 added to existing stakes and 7 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $8.75M. The largest seller was Virtu Financial, exiting entirely with an estimated $541K sold.

  • 59 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2018, up from 51 in Q4 2017.
  • Funds reported $62.7M of Viridian Therapeutics stock for Q1 2018, up 4.4% quarter-over-quarter.
  • 16 funds opened new Viridian Therapeutics positions in Q1 2018 and 7 closed out, a net change of +9 holders.
  • The largest Viridian Therapeutics buyer in Q1 2018 was Fidelity Investments, an estimated $8.75M added.
  • The largest Viridian Therapeutics seller in Q1 2018 was Virtu Financial, an estimated $541K sold.

Based on aggregated 13F filings for Q1 2018.